| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.91 [0.72, 1.14] | | < 1 | | 0% | 2 studies (2/-) | 79.5 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 0.94 [0.64, 1.37] | | < 1 | | 80% | 2 studies (2/-) | 62.7 % | low | not evaluable | high | important | - |
| DCR | 0.91 [0.63, 1.32] | | > 1 | | 0% | 1 study (1/-) | 31.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.97 [0.63, 1.49] | | > 1 | | 58% | 2 studies (2/-) | 44.3 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 14.27 [3.34, 61.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 4.03 [2.70, 6.00] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.30 [0.59, 2.84] | | < 1 | | 0% | 2 studies (2/-) | 25.7 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.78 [0.47, 1.29] | | < 1 | | 0% | 1 study (1/-) | 83.6 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.24 [0.85, 1.81] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.82 [0.11, 5.85] | | < 1 | | 0% | 1 study (1/-) | 57.9 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.41 [0.93, 2.12] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Arthralgia TRAE (grade 3-4) | 1.44 [0.48, 4.34] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 2.47 [0.45, 13.60] | | < 1 | | 0% | 1 study (1/-) | 15.1 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.30 [0.01, 6.77] | | < 1 | | 0% | 1 study (1/-) | 77.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.53 [0.16, 1.76] | | < 1 | | 0% | 1 study (1/-) | 84.8 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 3.70 [0.38, 35.82] | | < 1 | | 0% | 1 study (1/-) | 13.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.36 [0.78, 2.37] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.17 [0.02, 1.40] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.22 [0.24, 6.13] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.98 [0.53, 1.81] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.48 [0.09, 2.52] | | < 1 | | 0% | 1 study (1/-) | 80.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.98 [0.14, 7.03] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.74 [0.50, 6.04] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.98 [0.02, 49.71] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.74 [0.50, 6.04] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.98 [0.02, 49.71] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.97 [0.07, 58.97] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Dermatitis acneiform AE (grade 3-4) | 22.68 [1.32, 388.47] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 4.44 [1.47, 13.42] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.65 [0.39, 7.00] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.97 [0.07, 58.97] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.77 [0.73, 4.30] | | < 1 | | 0% | 1 study (1/-) | 10.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 3.00 [0.60, 15.03] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.99 [0.49, 8.06] | | < 1 | | 0% | 1 study (1/-) | 16.8 % | NA | not evaluable | | non important | - |
| Increased Lipase Level AE (grade 3-4) | 2.00 [0.59, 6.74] | | < 1 | | 0% | 1 study (1/-) | 13.2 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 10.02 [0.54, 184.60] | | < 1 | | 0% | 1 study (1/-) | 6.3 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.98 [0.06, 15.80] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.98 [0.02, 49.71] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 6.03 [0.72, 50.50] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 7.83 [1.77, 34.66] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
| Rash maculopapular AE (grade 3-4) | 7.98 [0.42, 151.89] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 12.08 [0.67, 217.70] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 2.49 [0.48, 12.97] | | < 1 | | 0% | 1 study (1/-) | 14.0 % | NA | not evaluable | | non important | - |
